BUZZ-Apollomics slumps as blood cancer drug fails trial** Biotech firm Apollomics' APLM.O shares fall ~30% to $6.63 premarket
** Company says its experimental blood cancer therapy in combination with chemotherapy failed to show favorable benefit in extending survival vs chemotherapy alone in a late-stage trial
** Apollomics was testing the therapy, uproleselan, in patients with relapsed or refractory acute myeloid leukemia $(AML.UK)$
** AML is a type of blood cancer that starts in the bone marrow and affects white blood cells
** As of last close, company's shares down ~90% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments